Table 4.
Association of Her2 and Ki-67 expression with clinicopathologic parameters in patients with non-metastatic gastric cancer
| Variable | Double negative, n = 49 | Ki-67 positive, n = 91 | Her2 positive, n = 21 | Double positive, n = 34 | χ2/F | Pa | |
|---|---|---|---|---|---|---|---|
| Age (years) | As continuous | 63 ± 11; 63 (56–70) | 63 ± 8; 65 (59–69) | 63 ± 10; 63 (55–71) | 66 ± 8; 67 (61–73) | 0.70 | 0.554 |
| Age group | < 60 years | 19 (39) | 25 (28) | 7 (33) | 7 (21) | 1.98 | 0.160 |
| 60–69 years | 17 (35) | 45 (50) | 6 (29) | 14 (41) | |||
| ≥ 70 years | 13 (27) | 21 (23) | 8 (38) | 13 (38) | |||
| Sex | Male | 37 (76) | 66 (73) | 15 (71) | 30 (88) | 0.77 | 0.379 |
| Tumor location | Gastric cardia and fundus | 26 (53) | 48 (53) | 12 (57) | 16 (47) | < 0.01 | 0.985 |
| Gastric body | 8 (16) | 16 (18) | 5 (24) | 9 (27) | |||
| Gastric antrum and pylorus | 15 (31) | 27 (29) | 4 (19) | 9 (27) | |||
| Differentiation grade | Well/Moderate | 7 (14) | 18 (20) | 9 (43) | 14 (41) | 11.01 | 0.001 |
| Poor/undifferentiated | 42 (86) | 73 (80) | 12 (57) | 20 (59) | |||
| Neural invasion | Yes | 10 (20) | 12 (13) | 6 (29) | 7 (21) | 0.44 | 0.506 |
| Cancer embolus | Yes | 10 (20) | 20 (22) | 4 (19) | 5 (15) | 0.12 | 0.733 |
| Tumor length (cm) | As continuous | 5.1 ± 2.1; 5.0 (3.5–6.5) | 4.8 ± 2.3; 4.5 (3.0–6.0) | 4.7 ± 2.6; 4.0 (3.0–5.0) | 4.4 ± 2.1; 4.0 (2.8–5.5) | 0.59 | 0.625 |
| Tumor width (cm) | As continuous | 4.0 ± 1.6; 4.0 (2.5–5.0) | 3.8 ± 1.9; 3.5 (2.5–5.0) | 3.6 ± 2.0; 3.0 (2.8–4.5) | 3.3 ± 1.5; 3.0 (2.5–4.0) | 0.84 | 0.474 |
| Metastatic lymph node | As continuous | 4 ± 5; 3 (0–7) | 4 ± 5; 2 (0–7) | 3 ± 5; 1 (0–6) | 3 ± 4; 2 (0–5) | 0.50 | 0.683 |
| Lymph node ratio | As continuous | 0.22 ± 0.23; 0.18 (0.00–0.32) | 0.20 ± 0.25; 0.09 (0.00–0.35) | 0.18 ± 0.26; 0.05 (0.00–0.28) | 0.19 ± 0.24; 0.11 (0.00–0.27) | 0.16 | 0.921 |
| pT stage | 1 | 2 (4) | 11 (12) | 3 (14) | 4 (12) | 6.88 | 0.009 |
| 2 | 1 (2) | 10 (11) | 4 (19) | 8 (24) | |||
| 3–4 | 46 (94) | 70 (77) | 14 (67) | 22 (65) | |||
| pN stage | 0 | 16 (33) | 33 (36) | 9 (43) | 12 (35) | 0.52 | 0.472 |
| 1 | 7 (14) | 16 (18) | 5 (24) | 6 (18) | |||
| 2 | 13 (27) | 19 (21) | 2 (10) | 9 (26) | |||
| 3 | 13 (27) | 23 (25) | 5 (24) | 7 (21) | |||
| pTNM stage | I | 2 (4) | 18 (20) | 5 (24) | 6 (18) | 5.24 | 0.022 |
| II | 13 (27) | 18 (20) | 6 (29) | 12 (35) | |||
| III | 34 (69) | 55 (60) | 10 (48) | 16 (47) |
Categorical data are shown as count (percentage [%]), and continuous data as mean ± standard deviation; median (interquartile range)
pTNM stage pathological tumor-node-metastasis stage, Her2 human epidermal growth factor receptor 2
aFor comparison across groups